Kiniksa Pharmaceuticals International, plc Stockholders Equity

Quick Answer

Kiniksa Pharmaceuticals International, plc reported Stockholders Equity of $567.61 million for fiscal year 2025.

Kiniksa Pharmaceuticals International, plc Stockholders Equity — Annual History

Fiscal Year Stockholders Equity YoY Change
2025 $567.61M +29.5%
2024 $438.44M -0.1%
2023 $438.84M +10.8%
2022 $396.15M +114.1%
2021 $185.04M -40.7%
2020 $311.94M +38.4%
2019 $225.42M -19.3%
2018 $279.27M +411.3%
2017 -$89.71M -248.6%
2016 -$25.73M

Quarterly Stockholders Equity

Quarter Ending Stockholders Equity YoY QoQ
September 30, 2025 $535.38M +22.5% +8.2%
June 30, 2025 $495.01M +13.8% +8.2%
March 31, 2025 $457.49M +5.9% +4.3%
December 31, 2024 $438.44M -0.1% +0.3%
September 30, 2024 $437.01M +7.9% +0.4%
June 30, 2024 $435.10M +5.7% +0.7%
March 31, 2024 $431.89M +10.7% -1.6%
December 31, 2023 $438.84M +10.8% +8.3%
  • Kiniksa Pharmaceuticals International, plc showed an increase of +29.5% in Stockholders Equity compared to the prior fiscal year.
  • Over the 2016–2025 period, Kiniksa Pharmaceuticals International, plc’s stockholders equity has grown by 2305.8% (from -$25.73 million to $567.61 million).
  • The most recent figure is from Kiniksa Pharmaceuticals International, plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment